Clinical study on the efficacy and safety of Jieyuwan in the treatment of epidemic stress, anxiety and depression (stagnation of liver Qi syndrome)

Dongfang Hospital Beijing University of Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

适应症

试验速览

暂无简介。

•(1) They voluntarily signed informed consent and were willing to participate in the research;
•(2) novel coronavirus pneumonia affects the state of anxiety and depression;
•(3) The total score of hospital anxiety and depression scale was more than 16, and the total score of anxiety and / or depression items was more than 8;
•(4) According to the diagnosis of liver qi stagnation syndrome;
•(5) Age: 18-65 years old (including 18 years old and 65 years old).

•(1) Patients with overdose of excitatory drugs, withdrawal reaction of hypnotic sedative drugs or anti anxiety drugs, and patients with acute panic disorder, obsessive-compulsive disorder, mania or schizophrenia;
•(2) Patients with anxiety disorder or depression diagnosis;
•(3) Patients who have suicide history or suicide tendency in the past;
•(4) Patients with organic mental disorders, psychoactive substances, non addictive substances and postpartum depression;
•(5) Patients with severe primary diseases of heart, brain, liver, kidney, hematopoiesis and urogenital system;
•(6) The patients who had used antidepressant, anti anxiety, antipsychotic western medicine and the same kind of traditional Chinese medicine treatment within 4 weeks before enrollment;
•(7) Those who are allergic to any component of the test drug or allergic constitution (allergic to more than two kinds of food or drugs);
•(8) Pregnant or preparing for pregnancy and lactation;
•(9) Patients who participated in or were participating in other clinical trials within one month before enrollment.

发起方

Dongfang Hospital Beijing University of Chinese Medicine